Boxerman, J. L., Zhang, Z., Safriel, Y., Larvie, M., Snyder, B. S., Jain, R., . . . Barboriak, D. P. (2013). Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: Results from the ACRIN 6677/RTOG 0625 Central Reader Study. Oxford University Press.
Chicago-stil citatBoxerman, Jerrold L., et al. Early Post-bevacizumab Progression On Contrast-enhanced MRI As a Prognostic Marker for Overall Survival in Recurrent Glioblastoma: Results From the ACRIN 6677/RTOG 0625 Central Reader Study. Oxford University Press, 2013.
MLA-referensBoxerman, Jerrold L., et al. Early Post-bevacizumab Progression On Contrast-enhanced MRI As a Prognostic Marker for Overall Survival in Recurrent Glioblastoma: Results From the ACRIN 6677/RTOG 0625 Central Reader Study. Oxford University Press, 2013.